Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

NAD+

Plain-language summaryIntrigue 70 / 100

NAD+ (nicotinamide adenine dinucleotide) is a cofactor every cell uses for energy production and signaling. NAD+ levels decline with age, driving research interest in supplementation as an anti-aging strategy. Available as injection or supplement. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

38/100

Foundational cellular cofactor with real aging biology, but precursors dominate the research frontier

Cap applied Foundational metabolite cap (max 38)

Look, NAD+ is perhaps the most important small molecule in cellular biology that you’d never call a novel research compound. It’s been known since Arthur Harden’s 1906 Nobel-adjacent work on yeast fermentation, and its three-way role as redox carrier, sirtuin substrate, and PARP feedstock has been textbook material for decades. Scoring a foundational cellular metabolite on research novelty is an odd exercise, but thats exactly what we’re doing, and the answer is honest: NAD+ the molecule doesn’t score well because we already understand it.

The supplementation angle is where things get more interesting, and it’s the reason NAD+ deserves more than a vitamins-and-minerals dismissal. Starting with the Guarente and Sinclair groups’ sirtuin work in the early 2010s, and accelerating through the Imai lab’s 2013 demonstration of age-related NAD+ decline in mice, a serious research community has built up around the depletion-with-aging hypothesis. The biology is real: NAD+ declines substantially in older mammals, SIRT1/SIRT3 activity tracks it, PARP activity rises with DNA damage and competes for the same pool, and CD38 upregulation in aging tissue may be a primary driver of the decline. That’s genuinely interesting territory.

Here’s the problem for this particular product: the direct oxidized free acid is almost never the molecule a serious investigator wants to work with for supplementation research. Poor oral bioavailability means precursors, specifically nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), do essentially everything NAD+ supplementation research needs, more efficiently and with cleaner dose-response curves in animal models. The precursors have the clinical trial basis; they have the Elysium and ChromaDex datasets; they have the longitudinal aging studies. Direct NAD+ infusion has been studied and the acute bioenergetic effects are real, but the programs that matter run on precursors.

What keeps this from scoring lower is bench utility. If you’re running sirtuin deacetylase assays, PARP activity assays, or CD38 kinetics, you need direct NAD+ as a substrate reference. It’s an essential reagent for characterizing the very enzyme systems that make the aging-NAD+ story interesting. That’s real value and we’d never argue otherwise.

As a research compound in the sense this library is built around, NAD+ is foundational background rather than frontier. The investigators doing the interesting work use it as a tool to study the pathways that deplete it, not as the experimental variable. If you’re chasing the sirtuin biology or the CD38 angle, look at precursors and CD38 inhibitors like apigenin or 78c. NAD+ is where the arrows point, not where the interesting questions live.

Novelty

25

Mechanism promise

48

In-category differentiation

30

Evidence quality

60

Translational signal

42

Research bench value

62

Rationale NAD+ is a century-old cofactor with genuine aging-research relevance, but the direct oxidized free acid form is outcompeted by NMN and NR precursors for supplementation research; bench utility as a substrate reference for sirtuin, PARP, and CD38 assays keeps it from bottoming out, but novelty and differentiation anchor the score well below where the aging biology alone might suggest.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pyridine nucleotide cofactor, redox carrier and substrate for sirtuins, PARPs, and CD38

An obligate intracellular dinucleotide cofactor essential for hundreds of enzymatic reactions, supplied for research use as the oxidized free acid form for parenteral or topical research.

Abstract

Nicotinamide adenine dinucleotide (NAD+; CAS 53-84-9; molecular formula C21H27N7O14P2; molecular weight 663.43) is a small-molecule pyridine dinucleotide cofactor that functions in three biologically distinct roles: as the dominant cellular electron-transfer cofactor in oxidative metabolism (where it cycles between the oxidized NAD+ and reduced NADH forms), as the substrate for the sirtuin family of NAD+-dependent deacetylases (which hydrolyze NAD+ to nicotinamide and ADP-ribose), and as the substrate for poly-ADP-ribose polymerases (PARPs) and the CD38 ecto-enzyme (both of which also consume NAD+). Cellular NAD+ concentrations are tightly regulated and decline substantially with age in humans and other mammals; the age-related decline correlates with reduced sirtuin activity, impaired DNA damage repair, and a constellation of metabolic dysfunctions that has motivated substantial research interest in NAD+ supplementation as a geroprotective intervention. The research-grade product supplied as “NAD+” is the oxidized free acid form, which has poor oral bioavailability but is suitable for parenteral administration in research models. Better-characterized parenteral approaches use NAD+ precursors (nicotinamide riboside NR and nicotinamide mononucleotide NMN), which are more efficiently absorbed orally and converted intracellularly to NAD+. Direct NAD+ administration in research-grade dosing has been used in study of cellular bioenergetics, neurological function, and metabolic endpoints. The compound is not approved by any regulatory authority for human or veterinary use as a therapeutic; NAD+ is also widely available as a food supplement under separate regulatory frameworks.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-013Open in new tab →

Download PDF →

Acquire NAD+ from the catalog

View NAD+ →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
Epitalon

Plain-language summaryIntrigue 74 / 100

Epitalon is a four-amino-acid peptide developed in Russia by Vladimir Khavinson. The compound is reported to support telomerase activity, the enzyme that maintains the protective caps on chromosomes. Russian research has linked it to longevity in animal studies; Western clinical evidence is limited. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

40/100

Single-lab-dominated telomerase peptide with an interesting premise but no independent replication to back it

Here’s the thing about Epitalon: the scientific story it’s trying to tell is genuinely interesting, but the narrator has a credibility problem. A 4-residue synthetic peptide that modulates telomerase activity and pineal function, potentially slowing biological aging at the cellular level, that’s a real research question worth asking. The problem is that almost every answer in the Epitalon literature comes from the same room in St. Petersburg.

The Khavinson group at the Institute of Bioregulation and Gerontology has produced the overwhelming majority of published work on this compound, beginning in the Soviet era and continuing through to recent years. That’s not automatically disqualifying; single-lab pioneers happen. But when the most-cited claims, telomerase induction in human fibroblasts, lifespan extension in rodent cohorts, melatonin normalization in aging animals, all trace back to the same consortium with limited independent replication, you’re reading a research program, not a scientific consensus. We dont dismiss it; we just cant trust it the way we’d want to.

Mechanistically, there’s something to work with. The telomerase modulation story is plausible at the cell-culture level; the 2009 Nobel for telomere biology validated the broader question even if Epitalon specifically hasnt earned that credibility. The pineal axis angle is interesting too, particularly for circadian biology research. And a small tetrapeptide with reported multi-axis effects gives you some bench flexibility if you’re specifically studying any of those systems. That’s why the bench value score isn’t zero.

What we can’t get past is the evidence layer. The human studies that exist are small, largely uncontrolled observational designs in elderly populations from that same general research context. There’s no multi-center replicated RCT. There’s no independent lab group that has picked this compound up and confirmed the headline findings. The multi-decade literature feels more like one lab’s belief system than a collaborative field.

For investigators who are specifically studying Khavinson-class bioregulator peptides as a category, Epitalon is the canonical reference point and you need to understand it. For anyone studying pineal function or telomere biology more broadly, it’s a secondary reference at best. We’d want to see at least one independent preclinical replication of the telomerase induction findings before putting serious resources behind this compound. Until then, it sits at the interesting-but-untrustworthy tier: worth knowing about, not worth prioritizing over more rigorously evidenced targets in the same longevity space.

Novelty

40

Mechanism promise

55

In-category differentiation

45

Evidence quality

25

Translational signal

30

Research bench value

35

Rationale Epitalon scores in the middle of the single-lab-only range: mechanism novelty is real (telomerase modulation plus pineal axis) but the Khavinson group dominates the literature almost entirely, and the few human studies are uncontrolled small-N observational designs with no independent replication of the headline findings.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic tetrapeptide telomerase modulator and bioregulator

A 4-residue synthetic peptide developed in St. Petersburg, studied principally for telomerase modulation, pineal function, and circadian rhythm endpoints in a literature dominated by a single research consortium.

Abstract

Epitalon (also Epithalon, Epithalone; sequence Ala-Glu-Asp-Gly; CAS 307297-39-8; molecular formula C14H22N4O9; molecular weight 390.35) is a synthetic tetrapeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues beginning in the 1980s. The compound was designed as a synthetic analog of an active fragment isolated from a bovine pineal gland extract (the original “Epithalamin” preparation) and is reported to modulate pineal melatonin secretion, support telomerase activity in cultured cell lines, and influence circadian gene expression. The published preclinical record is dominated almost entirely by the Khavinson group and affiliated St. Petersburg laboratories, which is the principal methodological concern in any rigorous review of the literature; independent replication of the most-cited findings (telomerase induction, lifespan extension in rodent models) is sparse. A small number of human studies have been published, primarily uncontrolled or small-sample clinical observation studies in elderly populations, which have been critically reviewed for methodological limitations. Reported activities span pineal function modulation, antioxidant effects, telomere length stabilization in cell culture models, and reduction of age-related pathology markers in animal studies. The compound is not approved by any regulatory authority for human or veterinary use outside of certain Russian clinical contexts where Epithalamin (the parent extract) has historical use. Investigators should approach the literature with awareness of the single-laboratory dominance and the limited independent replication.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-006Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026

←Previous Page

1 … 67 68 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.